CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
about
Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesisThe Human Ureaplasma Species as Causative Agents of ChorioamnionitisThe evolving role of chemical synthesis in antibacterial drug discovery.Strategies to prevent preterm birth.Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects.Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatmA platform for the discovery of new macrolide antibiotics.In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?Efficacy of Solithromycin (CEM-101) for Experimental Otitis Media Caused by Nontypeable Haemophilus influenzae and Streptococcus pneumoniaeMaternal administration of solithromycin, a new, potent, broad-spectrum fluoroketolide antibiotic, achieves fetal and intra-amniotic antimicrobial protection in a pregnant sheep model.In vitro activity of solithromycin against erythromycin-resistant Streptococcus agalactiae.Macrolide antibiotics in the ribosome exit tunnel: species-specific binding and action.Antibiotics in development targeting protein synthesis.3D-QSAR and molecular docking for the discovery of ketolide derivatives.Natural product and natural product derived drugs in clinical trials.New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae.Solithromycin (CEM-101): A New Fluoroketolide Antibiotic and Its Role in the Treatment of Gonorrhea.Macrolide resistance mechanisms in Enterobacteriaceae: Focus on azithromycin.Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae.Management of Gonorrhea in Adolescents and Adults in the United States.Determination of In Vitro Activities of Solithromycin at Different pHs and Its Intracellular Activity against Clinical Isolates of Neisseria gonorrhoeae from a Laboratory Collection.Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae.The wobbly status of ketolides: where do we stand?Large-scale preparation of key building blocks for the manufacture of fully synthetic macrolide antibiotics.
P2860
Q24606228-8B7A4CED-8538-4E9B-82CD-820AAEB4E6A2Q28067452-119AC449-B44F-4D5D-84CA-EFA274CB67B8Q34427652-190F8C6A-B731-4500-A48A-7E0423C7E673Q34540998-D04EA75A-E188-432B-A90F-11D4086337FAQ34932518-DB52355A-0522-486E-834C-FB01AF0573E4Q35044119-D51C6DF6-67EE-4573-BD16-D8FA9B82E528Q35941481-9B587CDF-875B-4B9E-9E8E-16EFC22C9DF1Q36021739-DE81E2F2-AAC9-4DF2-9BD8-B8F98D63027AQ36086360-434ED238-796C-40DE-8B16-2E2FD27C6233Q37203789-E062D5B8-7106-4A81-AE0A-1E55B8187837Q37544439-269DF769-D89A-4829-A62A-5E8D990203DDQ37643673-A413DE83-D8A9-4FDD-A7CA-6A4B2A21DE7BQ37970718-96D7F717-5BA8-4452-A653-7C2FF128F75BQ37970724-29031ACA-04F8-48B0-B71F-DFB1C64CC29BQ38084701-5CBBB021-4B46-4799-9C51-60E1E659EBECQ38247457-FF8FE065-6212-4511-ADB5-4B086A8D7C3DQ38675370-0B621AAD-2B8D-4115-A4F1-761EBBD56469Q38793951-C70B6F6C-F5F7-43BA-AADC-954B5938443CQ38804355-C48B891A-D315-42EC-B6A5-6D480FA0DCD9Q39026738-4A1EF6F1-AE80-4F83-BE71-220C49D6217FQ39766207-2DF27838-35EB-4A75-8162-782045A92BE3Q40279995-42D6233C-FDCC-4FEE-A6BB-7F024D2CA4F8Q42573047-59E9A943-D7DF-48C2-ABE4-249AA9384D10Q43165331-26AFB548-A850-4A88-817D-56BEA64AA01AQ43408523-C1CEE650-F9A2-459A-AEAC-2503179506DBQ50091487-56078C02-062C-4599-A8D4-582CF91D0120
P2860
CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
CEM-101, a novel fluoroketolid ...... ve and Gram-negative bacteria.
@ast
CEM-101, a novel fluoroketolid ...... ve and Gram-negative bacteria.
@en
CEM-101, a novel fluoroketolid ...... ve and Gram-negative bacteria.
@nl
type
label
CEM-101, a novel fluoroketolid ...... ve and Gram-negative bacteria.
@ast
CEM-101, a novel fluoroketolid ...... ve and Gram-negative bacteria.
@en
CEM-101, a novel fluoroketolid ...... ve and Gram-negative bacteria.
@nl
prefLabel
CEM-101, a novel fluoroketolid ...... ve and Gram-negative bacteria.
@ast
CEM-101, a novel fluoroketolid ...... ve and Gram-negative bacteria.
@en
CEM-101, a novel fluoroketolid ...... ve and Gram-negative bacteria.
@nl
P2093
P1476
CEM-101, a novel fluoroketolid ...... ve and Gram-negative bacteria.
@en
P2093
David J Farrell
Gary J Moet
Ronald N Jones
Shannon D Putnam
P304
P356
10.1016/J.DIAGMICROBIO.2009.10.013
P577
2010-04-01T00:00:00Z